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Summary
Background Recurrent cutaneous squamous cell carcinoma (cSCC) has been associ-
ated with an increased risk of local functional and aesthetic comorbidity, meta-
stasis and mortality.
Objectives To compare the risk of recurrence between Mohs micrographic surgery
(MMS) and standard excision for cSCC of the head and neck.
Methods This was a retrospective cohort study of all patients with a cSCC treated
with MMS or standard excision at the departments of dermatology of a secondary
or tertiary care hospital in the Netherlands between 2003 and 2012. To detect all
recurrences, patients were linked to the Dutch pathology registry. To compare
the risk of recurrence between MMS and standard excision, hazard ratios (HRs)
were used adjusted for clinical tumour size > 2 cm and deep tumour invasion.
Results A total of 579 patients with 672 cSCCs were included: 380 cSCCs were
treated with MMS and 292 with standard excision. The risk of recurrence was
8% (22 of 292) after standard excision during a median follow-up of 57 years
[interquartile range (IQR) 35–78], which was higher than the 3% (12 of 380)
after MMS during a median follow-up of 49 years (IQR 23–60). The cumula-
tive incidence of recurrence was higher for standard excision than for MMS dur-
ing the entire follow-up period of 86 years. Carcinomas treated with MMS were
at a three times lower risk of recurrence than those treated with standard excision
when adjusted for tumour size and deep tumour invasion (adjusted HR 031,
95% confidence interval 012–066).
Conclusions MMS might be superior to standard excision for cSCCs of the head and
neck because of a lower rate of recurrence.
What’s already known about this topic?
• Recurrent cutaneous squamous cell carcinoma has been associated with an increased
risk of local functional and aesthetic comorbidity, metastasis and mortality.
What does this study add?
• Risk of recurrence was 8% after standard excision, which was higher than the 3%
after Mohs micrographic surgery.
• Mohs micrographic surgery might be superior to standard excision for squamous
cell carcinomas of the head and neck because of a lower rate of recurrence.
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Cutaneous squamous cell carcinoma (cSCC) represent 20% of
all skin cancers. SCC is the second most common skin cancer
after basal cell carcinoma. At least one in 15 white people will
develop a cSCC before the age of 85 and the incidence is still
rising.1–4 These cSCCs rarely metastasize (4%) and the disease-
specific death rate is low (2%).2,5 However, because of the
frequent localization in the head and neck, treatment can lead
to major functional and aesthetic comorbidity.
In the Netherlands, cSCC is commonly treated with standard
excision. In the Dutch cSCC guideline, Mohs micrographic
surgery (MMS) is noted as an alternative for standard excision
for stage ≥ II, especially when standard excision would lead to
substantial functional or aesthetic comorbidity.6 In America it
is generally accepted that MMS is indicated in high-risk cSCC
and the American ‘appropriate use criteria for MMS’ state that
it is also appropriate to use MMS for stage I cSCC.7
MMS is superior to standard excision for facial aggressive or
recurrent basal cell carcinomas, because of the low recurrence
rate and maximum preservation of healthy tissue.8–10 Studies
on cSCC recurrence rates after surgery are sparse and it there-
fore remains unclear if MMS is better than standard excision
for cSCC. This large retrospective cohort study was conducted
to determine if the risk of cSCC recurrence is lower after MMS
than standard excision.
Materials and methods
This was a retrospective, comparative cohort study of cSCC
treated with MMS or standard excision at the dermatology
departments of a tertiary (Erasmus Medical Centre Cancer
Institute) or a secondary care hospital (Isala Hospital), both in
the Netherlands, between 2003 and 2012. The study was
exempted from approval by both institutional review boards.
Inclusion criteria were all histologically confirmed invasive
cSCCs of the head and neck that were completely excised with
MMS or standard excision and multiple cSCCs per patient were
included. The cSCCs that were incompletely excised with MMS
or standard excision were excluded from the analysis and
described separately. For standard excision, incomplete exci-
sion was postoperatively defined by a pathologist with the
standard vertical bread-loaf technique if cSCC was detected on
the excision margin (stage I) or if a tumour-free margin was
≤ 2 mm (≥ stage II).6 For MMS, incomplete excision was
postoperatively defined by a pathologist within the routine
quality check if cSCC was detected on the outermost fresh fro-
zen Mohs slide. The study involved four pathologists; all had
special training in skin cancer pathology and MMS.
The inclusion period differed per treatment modality and
study centre. Patients treated with MMS were included at the
tertiary care hospital between 1 January 2009 and 31 Decem-
ber 2012 because in the Netherlands MMS for cSCC was only
offered at the tertiary care hospital since 2008. Inclusion
started from 2009 to exclude the effect of a presumed learn-
ing curve during the first MMS year and continued until 2012
to have at least 5 years of follow-up. To prevent selection bias,
cSCCs treated with standard excision were included at the
tertiary care hospital between 1 January 2003 and 31 Decem-
ber 2007. At the secondary care hospital, standard excision
was the only surgical treatment option during the entire study
period and patients were included from 1 January 2008 to 31
December 2012. Selection bias because of the different inclu-
sion periods was not expected because the Dutch cSCC guide-
line did not change during the entire study period (2003–
2012).6 In both hospitals, it was recommended that patients
should visit a dermatologist routinely postoperatively for the
following 5 years.6
The following variables were extracted from electronic
patient files including pathology reports and standardized digi-
tal MMS files:11 patient age and sex, tumour location (in the
H-zone), recurrence before MMS or standard excision, clinical
tumour size > 2 cm, defect size > 2 cm and deep tumour
invasion (i.e. beyond the subcutaneous fat). These tumour
characteristics were recorded because they have been associ-
ated with a high risk of cSCC recurrence.12 Vital status, includ-
ing date of death, was obtained from the Dutch Municipal
Population Register until 1 August 2017.
Study outcome
The main outcome was cSCC recurrence. Recurrence was
defined as a histologically proven cSCC in or within 1 cm of
the scar. Furthermore, histologically confirmed cSCC metastasis
was recorded. To detect all histopathologically proven recur-
rences and metastases, patients were linked to the nationwide
network and registry of histology and cytopathology (Dutch
acronym: PALGA) on 1 August 2017.13 In the Netherlands, all
histopathology reports from every biopsy, excision or MMS
procedure are recorded in this database.
Follow-up
As explained above, the inclusion period for standard excision
started earlier (2003) than for MMS (2009). Therefore, the
median follow-up time after standard excision was suspected
to be longer than after MMS. This was accepted because all
patients had a follow-up of at least 5 years and the majority
of cSCC recurrences occur within 5 years.14 The maximum
follow-up time for patients treated with standard excision was
restricted to the maximum follow-up possible for patients
treated with MMS (i.e. 86 years, which was the time between
the start of MMS inclusion on 1 January 2009 until the PALGA
search on 1 August 2017).
Surgical procedures
Standard excision was performed in a standard manner by a
dermatologist (n = 7), or a resident (n = 10) under supervi-
sion of a dermatologist. The cSCCs were excised with margins
of 5 mm for stage I and 10 mm for ≥ stage II.6 Specimens
were postoperatively assessed by a pathologist with the stan-
dard vertical bread-loaf technique and haematoxylin and eosin
staining.
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MMS was performed in a standard manner by experienced
Mohs surgeons (n = 6, all dermatologists certified by the Euro-
pean Society for Micrographic Surgery), or a resident (n = 10)
under supervision of a Mohs surgeon. The cSCCs were excised
with a minimal margin of clinically tumour-free tissue. The
sample was directly compressed, frozen and sliced horizontally
by a trained MMS technician. The entire excision margins
were microscopically examined on the fresh frozen slides by a
Mohs surgeon. Residual tumour was mapped and subsequently
excised. The procedure was repeated until tumour clearance
was achieved.
Statistics
Differences between MMS and standard excision regarding the
studied variables were assessed with an exact test for binary
variables and with an independent sample t-test with boot-
strapping for continuous variables, to take within-patient cor-
relation into account. The length of follow-up per patient was
calculated as the number of years between surgery and end of
study (linkage to PALGA on 1 August 2017) or date of recur-
rence or date of death, whichever occurred first. Difference
between the rate of recurrence after MMS and standard exci-
sion was assessed with a cumulative incidence curve to take
into account the competing risk of death. Comparison of the
risk of recurrence after MMS and standard excision was
assessed with univariable and multivariable Cox proportional
hazards regression adjusted for clinical tumour size > 2 cm
and deep tumour invasion. The 95% confidence intervals (CIs)
and P-values for the univariable and multivariable regression
were obtained by applying bootstrapping to take within-
patient correlation into account. The proportional hazards
assumption was confirmed by log minus log plots. P-values
less than 005 (2-sided) were considered significant. SPSS
240 for Windows (IBM, Armonk, NY, U.S.A.) and SAS 94
(SAS Institute Inc., Cary, NC, U.S.A.) were used for statistical
analyses.
Results
In total, 631 patients with 738 cSCCs of the head and neck
were reviewed of which 383 cSCCs were treated with MMS
and 355 with standard excision (Fig. 1). Of the 355 cSCCs
that were treated with standard excision, 122 (34%) were
included at the tertiary care hospital and 233 (66%) at the
secondary care hospital. The baseline characteristics, the rate
of incompletely excised cSCCs and the rate of recurrences did
not differ between the included cases at the tertiary care
hospital and secondary care hospital.
Of the 738 cSCCS, three treated with MMS and 63 treated
with standard excision were excluded because of an incomplete
cSCC excision. All three treated with MMS were additionally
completely excised with re-MMS and did not recur or metasta-
size. No additional treatment was given in 21% (13 of 63) of
the incomplete standard excision cases, after which 38% (5 of
13) developed a recurrence and 15% (2 of 13) metastasized. An
additional treatment was given in 79% (50 of 63) of the incom-
plete standard excision cases (43 standard excision, five radio-
therapy, two MMS). After a re-standard excision, 21% (9 of 43)
developed a recurrence and 2% (1 of 43) metastasized.
Baseline characteristics
A total of 579 patients [401, 69% men, overall median age
76 years, interquartile range (IQR) 69–82] with 672 com-
pletely excised cSCCs were included; 380 cSCCs were treated
with MMS and 292 with standard excision. There were 513
patients with one included cSCC, 50 patients with two cSCCs,
eight patients with three cSCCs, six patients with four cSCCs,
one patient with five cSCCs and one patient with six cSCCs.
Fig 1. Flowchart of the cutaneous squamous cell carcinomas (cSCCs) of the head and neck that were treated with Mohs micrographic surgery
(MMS) or standard excision (SE). RT, radiotherapy.
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For MMS, most cSCCs were located on the nose (22%),
forehead (19%) and scalp (17%) followed by the auricular
region (15%), cheek and maxilla (11%), periocular region
(8%), perioral region and lips (6%) and neck (2%). For stan-
dard excision, most cSCCs were located on the auricular
region (24%), scalp (21%), cheek and maxilla (20%) and
forehead (20%), followed by the nose (7%), perioral region
and lips (5%), neck (3%) and periocular region (2%).
The cSCCs treated with MMS were significantly more often:
located in the H-zone, previously recurrent tumours, clinically
> 2 cm and more often had deep tumour invasion (Table 1).
Defects after MMS were more often ≤ 2 cm than after stan-
dard excision. Median number of Mohs stages needed for
tumour clearance was one (range 1–4).
Cutaneous squamous cell carcinoma recurrence
The risk of recurrence was 8% (22 of 292) after standard
excision during a median follow-up of 57 years (IQR 35–
78), which was higher than the 3% (12 of 380) after MMS
during a median follow-up of 49 years (IQR 23–60). The
cumulative incidence of recurrence was higher for standard
excision than for MMS during the entire follow-up period of
86 years (Figure 2).
After adjusting for tumour size and deep tumour invasion,
cSCCs treated with MMS were at a three times lower risk of
recurrence than standard excision [adjusted hazard ratio
(HR) 031, 95% CI 012–066] (Table 2). Of the 12 cSCC
recurrences after MMS, 33% (4 of 12) were located in the
H-zone, 50% (6 of 12) were previously recurrent tumours,
58% (7 of 12) had a clinical tumour size > 2 cm, 67% (8 of
12) had a defect size > 2 cm, 67% (8 of 12) had a deep
tumour invasion and none metastasized. Of the 22 cSCC
recurrences after standard excision, 32% (7 of 22) were
located in the H-zone, 9% (2 of 22) were previously recurrent
tumours, 9% (2 of 22) had a clinical tumour size > 2 cm,
77% (17 of 22) had a defect size > 2 cm, 27% (6 of 22) had
a deep tumour invasion and 5% (1 of 22) metastasized.
Discussion
Until now, a wide range of cSCC recurrence rates after MMS
(0–6%) and standard excision (0–15%) has been reported.15
One systematic review with pooled analysis by Lansbury et al.
Table 1 Differences between cutaneous squamous cell carcinomas (cSCCs) that were treated with Mohs micrographic surgery or standard excision
regarding the characteristics and events during follow-up
Characteristic Mohs micrographic surgery (n = 380) Standard excision (n = 292) P-value
Sexa
Men 262 (69) 219 (75) 0101
Women 118 (31) 73 (25)
Age, years: median (IQR)a 76 (69–81) 76 (68–82) 0694
Anatomical location
Head and neck, not H-zone 153 (40) 161 (55) < 0001
H-zone 227 (60) 131 (45)
Surgical history
Primary cSCC 311 (82) 266 (91) 0001
Previously recurrent cSCC 69 (18) 26 (9)
Tumour size
≤ 2 cm in diameter 256 (67) 274 (94) < 0001
> 2 cm in diameter 124 (33) 18 (6)
Defect size
≤ 2 cm in diameter 231 (61) 93 (32) < 0001
> 2 cm in diameter 149 (39) 199 (68)
Tumour invasion
Dermis 153 (40) 250 (86) < 0001
Deep 227 (60) 42 (14)
Events during follow-up
Follow-up, years: median (IQR) 49 (23–60) 57 (35–78) 0001
Recurrence
No 368 (97) 270 (92) 0013
Yes 12 (3) 22 (8)
Metastasis
No 377 (99) 287 (98) 0304
Yes 3 (1) 5 (2)
Deceased (cause unknown)
No 209 (55) 133 (46) 0016
Yes 171 (45) 159 (54)
Values are n (%) unless otherwise stated; percentages were rounded. Numbers in the table represent cSCCs. IQR, interquartile range. aA total
of 579 patients with 672 cSCCs were included.
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showed a lower, but nonsignificant average recurrence rate
after MMS (30%, 95% CI 22–39%; 10 studies, n = 1572)
compared with standard excision (54%, 95% CI 25–91%;
12 studies, n = 1144).15 However, the included studies had
heterogeneous inclusion criteria, small numbers of included
patients and a short follow-up duration with limited informa-
tion on those lost to follow-up.
Our study showed a lower recurrence risk of cSCC of the
head and neck after MMS (3%) than after standard excision
(8%) during a median follow-up of 5 years (IQR 3–7).
Although the median follow-up after standard excision was
longer (57 years, IQR 35–78) than after MMS (49 years,
IQR 23–60), the cumulative incidence of recurrence was
higher for standard excision than for MMS during the entire
follow-up period of 86 years (Fig. 2). When adjusted for
tumour size and deep tumour invasion, cSCCs treated with
MMS were found to be at a three times lower risk of recur-
rence than standard excision (adjusted HR 031, 95% CI
012–066) (Table 2). The difference in risk of recurrence
was probably underestimated because we could not adjust for
all high-risk tumour characteristics. However, because of con-
founding by indication of MMS (i.e. selection bias), cSCCs
treated with MMS were more often high-risk tumours than
cSCCs treated with standard excision (Table 1).
The lower risk of recurrence after MMS than standard exci-
sion is most likely because of the fact that with MMS the
entire excision margin is histologically reviewed. In contrast,
with standard excision only a small portion of the excision
margin is histologically reviewed, increasing the risk of a false
negative result (i.e. an undetected incomplete cSCC excision).
The excluded 18% of incompletely excised cSCCs with stan-
dard excision in our study was higher than expected based on
the study of Lansbury et al., which showed a pooled average
estimate of 88% (95% CI 54–130%; 11 studies, n =
2343).15 However, the included studies had heterogeneous
inclusion criteria (e.g. cSCC on the head and neck and else-
where) and used a wide range of excision margins (2 to
> 10 mm, or unspecified). A recent retrospective review of
Fig 2. Cumulative incidence curve of recurrence of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery
(MMS) compared with standard excision (SE).





Univariable Cox regression Multivariable Cox regression
HR (95% CI) P-value HR (95% CI) P-value
Intervention
Standard excision 292 (43) 22 (65) Reference 0031 Reference 0004
Mohs micrographic surgery 380 (57) 12 (35) 049 (023–094) 031 (012–066)
Tumour size, diameter
≤ 2 cm 530 (79) 26 (76) Reference 0346 Reference 0119
> 2 cm 142 (21) 8 (24) 070 (032–182) 189 (064–406)
Tumour invasion
Dermis 403 (60) 20 (59) Reference 0593 Reference 0164
Deep 269 (40) 14 (41) 082 (041–169) 180 (071–413)
Values are n (%) unless otherwise stated; percentages were rounded. HR, hazard ratio; CI, confidence interval.
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cSCCs of the head and neck reported 14% (51 of 364) of
incompletely excised cSCCs. However, this study included
invasive as well as in situ cSCCs.16
We found an extremely high recurrence rate (38%) and
metastasis (15%) for incompletely excised cSCCs that did not
receive an additional treatment. This underlines the impor-
tance of a complete cSCC excision. In only 1% of the MMS
cases, an incomplete cSCC excision was found with the rou-
tine postoperative external histological quality check. This
shows that the Mohs surgeons were very well able to detect
cSCC on fresh frozen Mohs slides and that MMS is an excellent
treatment to achieve tumour clearance.
Another advantage of MMS compared with standard excision,
beside the lower risk of cSCC recurrence and the excellent
tumour clearance, is the maximum preservation of healthy tis-
sue.10 Consistently, we found that after MMS, defects were
more often ≤ 2 cm (60%) compared with after standard exci-
sion (32%), while cSCCs treated with MMS were more often
> 2 cm (33%) compared with standard excision (6%).
Strengths of this study are the comparative design, the large
number of included cSCCs, the precise detection of recurrences
(elimination of loss to follow-up by the use of PALGA), the
long-term follow-up and the use of the cumulative incidence
curve. This study shows that it is important to report follow-up
data of at least 5 years: after standard excision, 77% (17 of 22)
of the recurrences occurred within 5 years whereas only 45%
(10 of 22) of the recurrences occurred within the first 2 years.
Our study was limited to a retrospective design. As a result
of missing data, we could not determine: tumour stage (mm
of tumour invasion, perineural invasion, lymphovascular inva-
sion and cSCC differentiation), disease-specific death, and
high-risk patients (i.e. immunosuppressed patients). We
excluded all SCCs that were treated with MMS during the first
year that MMS was performed for SCC at the tertiary care hos-
pital. It is uncertain if the learning period of 1 year was long
enough to exclude the presumed bias of a learning curve.
It is uncertain if our results can be generalized to other inter-
national dermatology and MMS services. Firstly, in this study
MMS and standard excision were performed by dermatologists,
residents and Mohs surgeons who were trained in the Nether-
lands. Secondly, the recommended excision margins in the
Dutch cSCC guideline are wider (i.e. 5 mm for stage I and
10 mm for ≥ stage II) than the British and American guidelines
recommend (i.e. 4 mm for stage I and 6 m for ≥ stage II).6,17,18
In conclusion, this study shows that MMS is an excellent
treatment option for patients with cSCC of the head and neck.
Although the results imply superiority of MMS compared with
standard excision for cSCC of the head and neck as a result of
fewer recurrences, conclusions must be made carefully
because of the limitations of the study design.
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